Acuta Capital Partners LLC Has $824,000 Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX)

Acuta Capital Partners LLC decreased its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 82.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,743 shares of the company's stock after selling 51,357 shares during the quarter. Acuta Capital Partners LLC's holdings in Arcellx were worth $824,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ACLX. FMR LLC raised its holdings in Arcellx by 22.8% during the fourth quarter. FMR LLC now owns 7,956,633 shares of the company's stock valued at $610,194,000 after buying an additional 1,477,360 shares in the last quarter. Gilead Sciences Inc. bought a new position in shares of Arcellx in the 4th quarter valued at approximately $515,418,000. Vanguard Group Inc. lifted its holdings in Arcellx by 35.3% in the 4th quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company's stock worth $255,385,000 after purchasing an additional 867,996 shares during the last quarter. RA Capital Management L.P. boosted its position in Arcellx by 50.5% during the fourth quarter. RA Capital Management L.P. now owns 2,787,327 shares of the company's stock worth $213,760,000 after purchasing an additional 935,848 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Arcellx by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,121,322 shares of the company's stock valued at $162,685,000 after purchasing an additional 220,711 shares during the last quarter. Institutional investors own 96.03% of the company's stock.

Insiders Place Their Bets

In related news, insider Christopher Heery sold 10,155 shares of Arcellx stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $63.79, for a total value of $647,787.45. Following the completion of the transaction, the insider now directly owns 37,486 shares of the company's stock, valued at $2,391,231.94. The trade was a 21.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kavita Patel sold 1,500 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $71.64, for a total transaction of $107,460.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,455 shares of company stock valued at $3,407,903. 6.24% of the stock is currently owned by corporate insiders.

Arcellx Price Performance

NASDAQ:ACLX traded down $1.07 during midday trading on Wednesday, reaching $51.74. The stock had a trading volume of 1,153,268 shares, compared to its average volume of 566,803. The stock has a market capitalization of $2.85 billion, a P/E ratio of -73.61 and a beta of 0.34. Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.37. The firm's fifty day simple moving average is $64.81 and its 200-day simple moving average is $73.40.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The business had revenue of $15.27 million during the quarter, compared to the consensus estimate of $27.42 million. On average, equities research analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).